WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo